Literature DB >> 25649538

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?

Toru Mizuguchi1,2, Toshihiko Torigoe3, Fukino Satomi4, Hiroaki Shima4, Goro Kutomi4, Shigenori Ota4, Masayuki Ishii4, Hiroshi Hayashi5, Sumiyo Asakura6, Yoshihiko Hirohashi3, Makoto Meguro4, Yasutoshi Kimura4, Toshihiko Nishidate4, Kenji Okita4, Masaho Ishino7, Atsushi Miyamoto8, Masamitsu Hatakenaka9, Noriyuki Sato3, Koichi Hirata4.   

Abstract

Pancreatic tumors are chemoresistant and malignant, and there are very few therapeutic options for pancreatic cancer, as the disease is normally diagnosed at an advanced stage. Although attempts have been made to develop vaccine therapies for pancreatic cancer for a couple of decades, none of the resultant protocols or regimens have succeeded in improving the clinical outcomes of patients. We herein review vaccines tested within the past few years, including peptide, biological and multiple vaccines, and describe the three sets of criteria used to evaluate the therapeutic activity of vaccines in solid tumors.

Entities:  

Keywords:  Immunomodulation; Pancreatic cancer; Vaccine

Mesh：

Substances：

Year:  2015        PMID： 25649538     DOI： 10.1007/s00595-015-1120-8

Source DB:  PubMed          Journal:  Surg Today        ISSN： 0941-1291            Impact factor:   2.540


  61 in total

1.  Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.

Authors:  Yukino Kimura; Jun Tsukada; Takeshi Tomoda; Hidenori Takahashi; Kazuhiro Imai; Kanae Shimamura; Makoto Sunamura; Yoshikazu Yonemitsu; Shigetaka Shimodaira; Shigeo Koido; Sadamu Homma; Masato Okamoto
Journal:  Pancreas       Date:  2012-03       Impact factor: 3.327

2.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

3.  A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.

Authors:  Hiroaki Yanagimoto; Hisanori Shiomi; Sohei Satoi; Takashi Mine; Hideyoshi Toyokawa; Tomohisa Yamamoto; Tohru Tani; Akira Yamada; A-Hon Kwon; Nobukazu Komatsu; Kyogo Itoh; Masanori Noguchi
Journal:  Oncol Rep       Date:  2010-09       Impact factor: 3.906

4.  Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.

Authors:  Hidekazu Kameshima; Tetsuhiro Tsuruma; Goro Kutomi; Hiroaki Shima; Yuji Iwayama; Yasutoshi Kimura; Masahumi Imamura; Toshihiko Torigoe; Akari Takahashi; Yoshihiko Hirohashi; Yasuaki Tamura; Tomohide Tsukahara; Takayuki Kanaseki; Noriyuki Sato; Koichi Hirata
Journal:  Cancer Sci       Date:  2012-12-16       Impact factor: 6.716

5.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

6.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

Authors:  Ramesh K Ramanathan; Kenneth M Lee; John McKolanis; Elizabeth Hitbold; Wolfgang Schraut; Arthur J Moser; Elizabeth Warnick; Theresa Whiteside; Jennifer Osborne; Hyoung Kim; Roger Day; Monica Troetschel; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2004-09-14       Impact factor: 6.968

7.  Identification of gastrin as a growth peptide in human pancreatic cancer.

Authors:  J P Smith; A P Fantaskey; G Liu; I S Zagon
Journal:  Am J Physiol       Date:  1995-01

8.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.

Authors:  S L Bernhardt; M K Gjertsen; S Trachsel; M Møller; J A Eriksen; M Meo; T Buanes; G Gaudernack
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

9.  A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma.

Authors:  Robert G Maki; Philip O Livingston; Jonathan J Lewis; Sylvia Janetzki; David Klimstra; Diann Desantis; Pramod K Srivastava; Murray F Brennan
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.487

10.  Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.

Authors:  T Hamada; Y Nakai; H Yasunaga; H Isayama; H Matsui; N Takahara; T Sasaki; K Takagi; T Watanabe; H Yagioka; H Kogure; T Arizumi; N Yamamoto; Y Ito; K Hirano; T Tsujino; M Tada; K Koike
Journal:  Br J Cancer       Date:  2014-03-18       Impact factor: 7.640
View more
  8 in total

1.  Necessity for autologous blood storage and transfusion in patients undergoing pancreatoduodenectomy.

Authors:  Yoshito Tomimaru; Kozo Noguchi; Keizo Dono
Journal:  Surg Today       Date:  2016-08-22       Impact factor: 2.549

2.  Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review.

Authors:  Yusuke Watanabe; Kazuyoshi Nishihara; Sokichi Matsumoto; Takafumi Okayama; Yuji Abe; Toru Nakano
Journal:  Surg Today       Date:  2016-10-04       Impact factor: 2.549

3.  Significance of lymph node metastasis in pancreatic neuroendocrine tumor.

Authors:  Katsunobu Taki; Daisuke Hashimoto; Shigeki Nakagawa; Nobuyuki Ozaki; Shinjiro Tomiyasu; Masaki Ohmuraya; Kota Arima; Takayoshi Kaida; Takaaki Higashi; Keita Sakamoto; Kazuya Sakata; Hirohisa Okabe; Hidetoshi Nitta; Hiromitsu Hayashi; Akira Chikamoto; Toru Beppu; Hiroshi Takamori; Masahiko Hirota; Hideo Baba
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

4.  The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.

Authors:  Daisaku Yamada; Hidetoshi Eguchi; Yoshifumi Iwagami; Tadafumi Asaoka; Takehiro Noda; Koichi Kawamoto; Kunihito Gotoh; Shogo Kobayashi; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2018-05-17       Impact factor: 2.549

5.  MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.

Authors:  Manabu Mikamori; Daisaku Yamada; Hidetoshi Eguchi; Shinichiro Hasegawa; Tomoya Kishimoto; Yoshito Tomimaru; Tadafumi Asaoka; Takehiro Noda; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Masaki Mori; Yuichiro Doki
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

6.  Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma.

Authors:  Katsunori Matsushita; Shogo Kobayashi; Hirofumi Akita; Masamitsu Konno; Ayumu Asai; Takehiro Noda; Yoshifumi Iwagami; Tadafumi Asaoka; Kunihito Gotoh; Masaki Mori; Yuichiro Doki; Hidetoshi Eguchi; Hideshi Ishii
Journal:  Cancer Rep (Hoboken)       Date:  2021-11-24

Review 7.  Immune responses to human cancer stem-like cells/cancer-initiating cells.

Authors:  Yoshihiko Hirohashi; Toshihiko Torigoe; Tomohide Tsukahara; Takayuki Kanaseki; Vitaly Kochin; Noriyuki Sato
Journal:  Cancer Sci       Date:  2015-11-12       Impact factor: 6.716

Review 8.  Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma.

Authors:  Olga Wysocka; Julita Kulbacka; Jolanta Saczko
Journal:  Prz Gastroenterol       Date:  2016-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.